Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, ...

Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied ...

Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs ...

Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, ...

As publishers and research platforms such as Reaxys and Springer Nature build application programming interface (API) access ...

Thermo Fisher Scientific announced it is showcasing new and expanded services at CPHI Milan, which is happening from October 6-8, 2026. The company will be presenting new drug dev ...

Access Part 1 of this interview in which Scarboro explains why real-world usability belongs at product definition. Access ...

The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor ...

The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label ...

Pharmaceutical Technology Europe | Publications | Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and expert industry news.

Pharmaceutical Technology | Publications | Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and expert industry news.

Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical ...